BioCentury
ARTICLE | Clinical News

Ipatasertib: Phase II data

May 23, 2016 7:00 AM UTC

A double-blind, placebo-controlled, international Phase II trial in 253 patients with metastatic CRPC previously treated with docetaxel showed that once-daily 400 mg oral ipatasertib plus Zytiga abir...